Evidence map›Paper›PMID 34216724›Full record

ArticleJournal of hepatology2021

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Lichun Ma, Limin Wang, Subreen A Khatib, Ching-Wen Chang, Sophia Heinrich, Dana A Dominguez, Marshonna Forgues, Julián Candia, Maria O Hernandez, Michael Kelly and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 234 papers.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed
24.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 365 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Lichun MaLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Limin WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Subreen A KhatibLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Ching-Wen ChangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Sophia HeinrichLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Dana A DominguezLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Marshonna ForguesLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Julián CandiaLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Maria O HernandezFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 20701 USA.
Michael KellyFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 20701 USA.
Yongmei ZhaoFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 20701 USA.
Bao TranFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 20701 USA.
Jonathan M HernandezSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Jeremy L DavisSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
David E KleinerLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA.
Bradford J WoodLiver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA; NIH Center for Interventional Oncology, Bethesda, Maryland 20892 USA.
Tim F GretenLiver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA. Electronic address: tim.greten@nih.gov.
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 USA. Electronic address: xw3u@nih.gov.
National Cancer Institute · USLeidos (United States) · US

Funding

CCR Sequencing FacilityZICBC011331 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALIK, MARIAM · 2010 to 2025
$68.2M
Interrogating the molecular underpinnings of metastatic colonizationZIABC011759 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2017 to 2025
$18.9M
Strategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1M
The role of cancer stem cells in liver cancer heterogeneity and subtypesZIABC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$12.6M
Liver Cancer ProgramZIABC011870 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2019 to 2025
$10.1M
The identification of human hepatocellular carcinoma metastasis genesZIABC010877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$8.3M
Molecular signatures for liver cancer diagnosis and treatment stratificationZ01BC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 1999 to 2008
$1.8M
The identification of human hepatocellular carcinoma metastasis genesZ01BC010877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$327k
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
Intramural NIH HHS Z01 BC010313Intramural NIH HHS Z01 BC010877Intramural NIH HHS ZIA BC010313Intramural NIH HHS ZIA BC010876Intramural NIH HHS ZIA BC010877Intramural NIH HHS ZIA BC011870
6 · The paper itself

Abstract

BACKGROUND &

aimsIntratumor molecular heterogeneity is a key feature of tumorigenesis and is linked to treatment failure and patient prognosis. Herein, we aimed to determine what drives tumor cell evolution by performing single-cell transcriptomic analysis.

methodsWe analyzed 46 hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) biopsies from 37 patients enrolled in interventional studies at the NIH Clinical Center, with 16 biopsies collected before and after treatment from 7 patients. We developed a novel machine learning-based consensus clustering approach to track cellular states of 57,000 malignant and non-malignant cells including tumor cell transcriptome-based functional clonality analysis. We determined tumor cell relationships using RNA velocity and reverse graph embedding. We also studied longitudinal samples from 4 patients to determine tumor cellular state and its evolution. We validated our findings in bulk transcriptomic data from 488 patients with HCC and 277 patients with iCCA.

resultsUsing transcriptomic clusters as a surrogate for functional clonality, we observed an increase in tumor cell state heterogeneity which was tightly linked to patient prognosis. Furthermore, increased functional clonality was accompanied by a polarized immune cell landscape which included an increase in pre-exhausted T cells. We found that SPP1 expression was tightly associated with tumor cell evolution and microenvironmental reprogramming. Finally, we developed a user-friendly online interface as a knowledge base for a single-cell atlas of liver cancer.

conclusionsOur study offers insight into the collective behavior of tumor cell communities in liver cancer as well as potential drivers of tumor evolution in response to therapy. LAY SUMMARY: Intratumor molecular heterogeneity is a key feature of tumorigenesis that is linked to treatment failure and patient prognosis. In this study, we present a single-cell atlas of liver tumors from patients treated with immunotherapy and describe intratumoral cell states and their hierarchical relationship. We suggest osteopontin, encoded by the gene SPP1, as a candidate regulator of tumor evolution in response to treatment.

Indexed as

BiopsyCarcinoma, HepatocellularCholangiocarcinomaHumansImmunotherapyLiver NeoplasmsNeoplastic Cells, CirculatingFunctional clonalityLiver cancerOsteopontinSingle cellT cellsTumor cell stateTumor evolutionTumor microenvironmentsTumor transcriptomic heterogeneity

Identifiers

PMID34216724
PMCPMC8604764
OpenAlexW3175283754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.